FDA PRE-APPROVAL INSPECTIONS RESULT IN 62% "TURNDOWN" RATE

FDA PRE-APPROVAL INSPECTIONS RESULT IN 62% "TURNDOWN" RATE from agency field staff recommendations, FDA Mid-Atlantic Region, Assistant Regional Food and Drug Director Joseph Phillips told a Jan. 31 Regulatory Affairs Professionals Society meeting. Of 384 inspections FDA completed from the beginning of the program in 1990 to the end of the year, he said, FDA is "recommending withholding approval on 237 of them." Phillips noted that "a little mathematics shows you that's a 62% [recommendation] turn- down rate. That's fairly high." The field staff recommended approval after the 147 other inspections. In total, FDA's Office of Compliance sent the district offices 644 requests for inspections during 1990. These requests involved NDAs, ANDAs and applications involving vendors and control labs. Of the 644 requests "the district directors are opting to inspect 384," Phillips said. The district offices decided that 225 of the applications did not require inspections. The FDA field staff recommended approval of 225 applications without resorting to pre-approval inspections based on "intelligence gathering." Counting the 147 approval recommendations following inspections, the field staff recommended a total of 372 applications for approval in 1990. Also speaking at the RAPS meeting, Office of Compliance Director Daniel Michels noted that the inspections are finding violations at an "unacceptably high rate." Several weeks ago, Michels told the National Association of Pharmaceutical Manufacturers' annual meeting that "serious" good manufacturing practice deficiencies have been discovered in about one of every three pre-approval inspections ("The Pink Sheet" Jan. 28, p. 5). Phillips reported that FDA is going to ask sponsors to submit a third copy of certain sections of NDAs or ANDAs to the agency to aid investigators during pre-approval inspections. The proposed rule requesting this additional submission was published in the Jan. 28 Federal Register. FDA is proposing in the notice that applicants of NDAs, ANDAs, and supplemental applications submit "an additional review copy of the chemistry and biopharmaceutics" and "an additional copy of the applicant's draft labeling." FDA also indicated that it may require in the chemistry, manufacturing and controls section "certain information concerning the batches used to perform bioavailability, bioequivalence, and stability tests, the master production record for a commercial lot, and the results of component testing" if that information is not "ordinarily" required. The extra copies will be used "during a pre-approval inspection to audit application commitments against actual manufacturing practices used by applicants." The notice points out that investigators usually do not have access to information in applications before or during an inspection unless they use the applicant's own copy of an NDA or ANDA. Comments on the proposed rule are due by March 29, 1991.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

Ocaliva: Still No Clarity On Why EU Court Opposed Revocation Of Approval

 

Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By 

This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By 

We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.

Brazil Pilots Digital Drug Pack Inserts

 

A new pilot aims to take Brazil closer to ‘digital transformation.’

More from Pink Sheet

Industry Criticizes Dutch Decision To Slash PARP Inhibitor Reimbursement

 

ZIN, the Dutch health technology assessment body, estimates that the number of patients eligible for treatment with a PARP inhibitor will be halved following a reassessment of drugs in the class.

EU Biosimilar Filings, Opinions And Approvals

 

A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.

US FDA’s ADHD Drug Relabeling Advances A MAHA Priority, Reviving Data Dispute

 

Extended-release stimulants will add a new ‘Limitation of Use’ about weight loss in children under 6 years, reflecting concerns about overuse from the Make America Healthy Again commission, a concern multiple studies did not find valid.